Metabolic associated liver disease (MAFLD) formally known as nonalcoholic faty liver disease (NAFLD) affects about 20% to 30% of the global population and increases the risk for hepatic and extrahepatic complications, including cardiovascular disease, diabetes, and some types of cancer
(2023). Insulin resistance as a risk factor for metabolic-associated fatty liver disease (MAFLD) in non-obese individuals. Egyptian Society of Diabetes and Lipidology Journal, 3(2), -. doi: 10.21608/esdlj.2023.456188
MLA
. "Insulin resistance as a risk factor for metabolic-associated fatty liver disease (MAFLD) in non-obese individuals", Egyptian Society of Diabetes and Lipidology Journal, 3, 2, 2023, -. doi: 10.21608/esdlj.2023.456188
HARVARD
(2023). 'Insulin resistance as a risk factor for metabolic-associated fatty liver disease (MAFLD) in non-obese individuals', Egyptian Society of Diabetes and Lipidology Journal, 3(2), pp. -. doi: 10.21608/esdlj.2023.456188
VANCOUVER
Insulin resistance as a risk factor for metabolic-associated fatty liver disease (MAFLD) in non-obese individuals. Egyptian Society of Diabetes and Lipidology Journal, 2023; 3(2): -. doi: 10.21608/esdlj.2023.456188
)
